Angiogenesis inhibitor BT2 is a novel inhibitor of angiogenesis and vascular permeability, inhibiting ERK phosphorylation and the expression of FosB ΔFosB, VCAM-1, and many genes involved in proliferation, migration, angiogenesis, and inflammation, interacting with MEK1, suppressing retinal CD31, pERK, VCAM-1, and VEGF-A165 expression.
7,8-Didehydrocimigenol can be used for the treatment of cardiovascular disorders such as atherosclerosis. It upregulates PPAR-γ in EC inhibits NF-kB activity of TNF-α-activated EC which leads to selective inhibition of VCAM-1 expression.
Cimiside E has anti-inflammatory activity, it selectively inhibits TNF-α-induced expression of VCAM-1 at least by upregulation of PPAR-γ, and signals for ERK1 2, PI3K, and PKC are involved in this effect.Cimiside E may be an effective chemopreventive agen
Pyranonigrin A is a fungal metabolite originally isolated from Aspergillus that has antioxidant activity. It scavenges 2,2-diphenyl-1-picrylhydrazyl (DPPH;) free radicals in a cell-free assay (IC50 = 132.9 μM). Pyranonigrin A (10 μM) suppresses TNF-α-induced expression of vascular cell adhesion molecule 1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs).
HMR1031 is a potent and specific integrin α4ß1 or very late antigen 4 (VLA-4) receptor antagonist which binds to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin.